These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

53 related articles for article (PubMed ID: 14582366)

  • 1. Insights from Therapeutic Studies for PrP Prion Disease.
    Teruya K; Doh-Ura K
    Cold Spring Harb Perspect Med; 2017 Mar; 7(3):. PubMed ID: 27836910
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quinacrine promotes replication and conformational mutation of chronic wasting disease prions.
    Bian J; Kang HE; Telling GC
    Proc Natl Acad Sci U S A; 2014 Apr; 111(16):6028-33. PubMed ID: 24711410
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapies for human prion diseases.
    Panegyres PK; Armari E
    Am J Neurodegener Dis; 2013 Sep; 2(3):176-86. PubMed ID: 24093082
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regulation of prion protein expression: a potential site for therapeutic intervention in the transmissible spongiform encephalopathies.
    Haigh CL; Brown DR
    Int J Biomed Sci; 2006 Dec; 2(4):315-23. PubMed ID: 23674999
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quinacrine impairs enterovirus 71 RNA replication by preventing binding of polypyrimidine-tract binding protein with internal ribosome entry sites.
    Wang J; Du J; Wu Z; Jin Q
    PLoS One; 2013; 8(1):e52954. PubMed ID: 23301007
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rapidly progressive dementias and the treatment of human prion diseases.
    Appleby BS; Lyketsos CG
    Expert Opin Pharmacother; 2011 Jan; 12(1):1-12. PubMed ID: 21091283
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of encephalomyocarditis virus and poliovirus replication by quinacrine: implications for the design and discovery of novel antiviral drugs.
    Gasparian AV; Neznanov N; Jha S; Galkin O; Moran JJ; Gudkov AV; Gurova KV; Komar AA
    J Virol; 2010 Sep; 84(18):9390-7. PubMed ID: 20631142
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of novel acridine derivatives in the inhibition of hPrP90-231 prion protein fragment toxicity.
    Villa V; Tonelli M; Thellung S; Corsaro A; Tasso B; Novelli F; Canu C; Pino A; Chiovitti K; Paludi D; Russo C; Sparatore A; Aceto A; Boido V; Sparatore F; Florio T
    Neurotox Res; 2011 May; 19(4):556-74. PubMed ID: 20405353
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and efficacy of quinacrine in human prion disease (PRION-1 study): a patient-preference trial.
    Collinge J; Gorham M; Hudson F; Kennedy A; Keogh G; Pal S; Rossor M; Rudge P; Siddique D; Spyer M; Thomas D; Walker S; Webb T; Wroe S; Darbyshire J
    Lancet Neurol; 2009 Apr; 8(4):334-44. PubMed ID: 19278902
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MRI and clinical syndrome in dura mater-related Creutzfeldt-Jakob disease.
    Meissner B; Kallenberg K; Sanchez-Juan P; Ramljak S; Krasnianski A; Heinemann U; Eigenbrod S; Gelpi E; Barsic B; Kretzschmar HA; Schulz-Schaeffer WJ; Knauth M; Zerr I
    J Neurol; 2009 Mar; 256(3):355-63. PubMed ID: 19159063
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics of quinacrine in the treatment of prion disease.
    Yung L; Huang Y; Lessard P; Legname G; Lin ET; Baldwin M; Prusiner SB; Ryou C; Guglielmo BJ
    BMC Infect Dis; 2004 Nov; 4():53. PubMed ID: 15569390
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Creutzfeldt-Jakob disease in patients who received a cadaveric dura mater graft--Spain, 1985-1992.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 1993 Jul; 42(28):560-3. PubMed ID: 8326950
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Creutzfeldt-Jakob disease in a patient with a lyophilized dura mater graft.
    Liscić RM; Brinar V; Miklić P; Barsić B; Himbele J
    Acta Med Croatica; 1999; 53(2):93-6. PubMed ID: 10705627
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinicopathologic characteristics of five autopsied cases of dura mater-associated Creutzfeldt-Jakob disease.
    Iwasaki Y; Mimuro M; Yoshida M; Hashizume Y; Kitamoto T; Sobue G
    Neuropathology; 2008 Feb; 28(1):51-61. PubMed ID: 18181835
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Creutzfeldt-Jakob disease transmitted by cadaveric dural graft: a case report].
    Takayama S; Hatsuda N; Matsumura K; Nakasu S; Handa J
    No Shinkei Geka; 1993 Feb; 21(2):167-70. PubMed ID: 8459905
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Quinacrine administration to a patient with Creutzfeldt-Jakob disease who received a cadaveric dura mater graft--an EEG evaluation].
    Kobayashi Y; Hirata K; Tanaka H; Yamada T
    Rinsho Shinkeigaku; 2003 Jul; 43(7):403-8. PubMed ID: 14582366
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Creutzfeldt-Jakob disease acquired via a dural graft: failure of therapy with quinacrine and chlorpromazine.
    Martínez-Lage JF; Rábano A; Bermejo J; Martínez Pérez M; Guerrero MC; Contreras MA; Lunar A
    Surg Neurol; 2005 Dec; 64(6):542-5, discussion 545. PubMed ID: 16293480
    [TBL] [Abstract][Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.